{
    "q": [
        {
            "docid": "23890524_15",
            "document": "Eukaryotic ribosome (80S) . The ribosome is a prominent drug target and many antibacterials interfere with translation at different stages of the elongation cycle Most clinically relevant translation compounds are inhibitors of bacterial translation, but inhibitors of eukaryotic translation may also hold therapeutic potential for application in cancer or antifungal chemotherapy. Elongation inhibitors show antitumor activity 'in vivo' and 'in vitro'. One inhibitor of eukaryotic translation elongation is the glutarimide antibiotic cycloheximide (CHX), which was co-crystallized with the eukaryotic 60S subunit and binds in the ribosomal E-site. The structural characterization of the eukaryotic ribosome enables the use of structure-based methods for the design of novel therapeutics, and allows the structural differences to the bacterial ribosome to be exploited, improving the selectivity and drug and therefore reducing adverse effects.",
            "score": 72.42592144012451
        },
        {
            "docid": "1551873_30",
            "document": "ATP-binding cassette transporter . Bacterial drug resistance has become an increasingly major health problem. One of the mechanisms for drug resistance is associated with an increase in antibiotic efflux from the bacterial cell. Drug resistance associated with drug efflux, mediated by P-glycoprotein, was originally reported in mammalian cells. In bacteria, Levy and colleagues presented the first evidence that antibiotic resistance was caused by active efflux of a drug. P-glycoprotein is the best-studied efflux pump and as such has offered important insights into the mechanism of bacterial pumps. Although some exporters transport a specific type of substrate, most transporters extrude a diverse class of drugs with varying structure. These transporters are commonly called multi-drug resistant (MDR) ABC transporters and sometimes referred to as \"hydrophobic vacuum cleaners\".",
            "score": 71.2712459564209
        },
        {
            "docid": "57413297_2",
            "document": "Murepavadin . The host defense antimicrobial peptide protegrin I (PG-1), exhibits broad-spectrum antimicrobial activity and good activity against multi-drug resistant Gram-negative pathogens, with a mechanism consistent with membrane disruption via pore formation. However, PG-1 exhibits unfavorable drug properties and also exhibits significant hemolysis and, as such, has limited clinical use. PG-1 contains 18 amino acids and is ordered into an anti-parallel \u03b2-strand by two disulfide bridges. A fully synthetic cyclic peptide-like molecule containing a D-proline\u2013L-proline template grafted into a peptidomimetic scaffold to simulate and stabilize the beta hairpin conformation exhibited by PG-1 was used to generate a diverse library of peptidomimetic macrocycles which were screened for antibacterial activity. Variants in this 14-residue protein epitope mimetic (PEM) library such as the peptidomimetic L8-1 had an antimicrobial activity like that of PG-1 but with reduced hemolytic activity on human red blood cells. Iterative rounds of synthesis generated analogues with an increasingly potent and selective profile producing nanomolar range compounds specifically against Pseudomonas spp. at the expense of broad-spectrum activity. Final optimization led to the discovery of murepavadin, with remarkable Pseudomonas-specific activity \"in vitro\" and \"in vivo\" that has high plasma stability across species and is non-hemolytic at 100\u00a0\u00b5g/mL. Structure\u2013activity relationship (SAR) studies showed that aromatic side chains of Trp2 and Trp8 are very important for antibiotic activity, while NMR studies showed that these potent D-Pro-L-Pro antibiotic derivatives had a stable \u03b2- hairpin conformation in aqueous solution whereas related derivatives with the D-Pro-L-Pro template inverted to L-Pro-D-Pro, shows no stable hairpin conformation and the antimicrobial activity was lost, suggesting that the \u03b2-hairpin structure is crucial for interaction with the bacterial target. Murepavadin functions through a novel mechanism of action by binding to the lipopolysaccharide (LPS) transport protein D (LptD), an outer membrane protein involved in lipopolysaccharide biogenesis in Gram-negative bacteria. By binding to LptD, murepavadin inhibit the LPS transport function of LptD and causes lipopolysaccharide alterations in the outer membrane of the bacterium and, ultimately, cell death.",
            "score": 75.42142927646637
        },
        {
            "docid": "44981660_7",
            "document": "Eleftheria terrae . \"E. terrae\"s production of teixobactin is prominent because recent tests have revealed that teixobactin binds differently than most normally used antibiotics which makes it harder for the bacteria being attacked to develop resistance. Experiments performed by Ling et al. have shown teixobactin is capable of binding to lipid precursors of peptidoglycan, which makes up part of bacterial cell walls. The results did not show any resistance to teixobactin in the organisms that were studied, including \"Staphylococcus aureus\" and \"Mycobacterium tuberculosis\". These findings indicate that teixobactin's target is not a protein, leading to the belief that the development of bacterial resistance to teixobactin is much less likely. These experiments also showed that teixobactin followed a similar mechanism of action as the antibiotic vancomycin that binds to the lipid II molecule in peptidoglycan precursors but, unlike vancomycin, teixobactin is capable of binding to modified lipid II molecules found in vancomycin resistant bacteria. Teixobactin's inhibition of peptidoglycan synthesis is further explained by Ling's finding of a buildup of undecaprenyl-N-acetylmuramic acid-pentapeptide, a crucial step in the biosynthesis of peptidoglycan. According to Ling's tests, teixobactin is capable of inhibiting peptidoglycan synthesis by binding to either lipid I, lipid II, and undecaprenyl pyrophosphate. Teixobactin also seemed to be specifically involved with peptidoglycan precursors rather than blocking enzyme activity.",
            "score": 73.41637945175171
        },
        {
            "docid": "2065768_4",
            "document": "Antimicrobial peptides . The modes of action by which antimicrobial peptides kill microbes are varied, and may differ for different bacterial species. Some antimicrobial peptides kill both bacteria and fungi, e.g., psoriasin kills \"E. coli\" and several filamentous fungi. The cytoplasmic membrane is a frequent target, but peptides may also interfere with DNA and protein synthesis, protein folding, and cell wall synthesis. The initial contact between the peptide and the target organism is electrostatic, as most bacterial surfaces are anionic, or hydrophobic, such as in the antimicrobial peptide Piscidin. Their amino acid composition, amphipathicity, cationic charge and size allow them to attach to and insert into membrane bilayers to form pores by \u2018barrel-stave\u2019, \u2018carpet\u2019 or \u2018toroidal-pore\u2019 mechanisms. Alternately, they may penetrate into the cell to bind intracellular molecules which are crucial to cell living. Intracellular binding models includes inhibition of cell wall synthesis, alteration of the cytoplasmic membrane, activation of autolysin, inhibition of DNA, RNA, and protein synthesis, and inhibition of certain enzymes. However, in many cases, the exact mechanism of killing is not known. One emerging technique for the study of such mechanisms is dual polarisation interferometry. In contrast to many conventional antibiotics these peptides appear to be bactericidal instead of bacteriostatic. In general the antimicrobial activity of these peptides is determined by measuring the minimal inhibitory concentration (MIC), which is the lowest concentration of drug that inhibits bacterial growth.",
            "score": 83.00951147079468
        },
        {
            "docid": "1491100_29",
            "document": "Flavin adenine dinucleotide . New design of anti-bacterial medications is of continuing importance in scientific research as bacterial antibiotic resistance to common antibiotics increases. A specific metabolic protein that uses FAD (Complex II) is vital for bacterial virulence, and so targeting FAD synthesis or creating FAD analogs could be a useful area of investigation. Already, scientists have determined the two structures FAD usually assumes once bound: either an extended or a butterfly conformation, in which the molecule essentially folds in half, resulting in the stacking of the adenine and isoalloxazine rings. FAD imitators that are able to bind in a similar manner but do not permit protein function could be useful mechanisms of inhibiting bacterial infection. Alternatively, drugs blocking FAD synthesis could achieve the same goal; this is especially intriguing because human and bacterial FAD synthesis relies on very different enzymes, meaning that a drug made to target bacterial FAD synthase would be unlikely to interfere with the human FAD synthase enzymes.",
            "score": 77.9420474767685
        },
        {
            "docid": "106256_31",
            "document": "Allosteric regulation . Allostery is a direct and efficient means for regulation of biological macromolecule function, produced by the binding of a ligand at an allosteric site topographically distinct from the orthosteric site. Due to the often high receptor selectivity and lower target-based toxicity, allosteric regulation is also expected to play an increasing role in drug discovery and bioengineering. The AlloSteric Database (ASD, http://mdl.shsmu.edu.cn/ASD) provides a central resource for the display, search and analysis of the structure, function and related annotation for allosteric molecules. Currently, ASD contains allosteric proteins from more than 100 species and modulators in three categories (activators, inhibitors, and regulators). Each protein is annotated with detailed description of allostery, biological process and related diseases, and each modulator with binding affinity, physicochemical properties and therapeutic area. Integrating the information of allosteric proteins in ASD should allow the prediction of allostery for unknown proteins, to be followed with experimental validation. In addition, modulators curated in ASD can be used to investigate potential allosteric targets for a query compound, and can help chemists to implement structure modifications for novel allosteric drug design.",
            "score": 72.18289601802826
        },
        {
            "docid": "209023_12",
            "document": "Streptomycin . Streptomycin is a protein synthesis inhibitor. It binds to the small 16S rRNA of the 30S subunit of the bacterial ribosome, interfering with the binding of formyl-methionyl-tRNA to the 30S subunit. This leads to codon misreading, eventual inhibition of protein synthesis and ultimately death of microbial cells through mechanisms that are still not understood. Speculation on this mechanism indicates that the binding of the molecule to the 30S subunit interferes with 50S subunit association with the mRNA strand. This results in an unstable ribosomal-mRNA complex, leading to a frameshift mutation and defective protein synthesis; leading to cell death. Humans have ribosomes which are structurally different from those in bacteria, so the drug does not have this effect in human cells. At low concentrations, however, streptomycin only inhibits growth of the bacteria by inducing prokaryotic ribosomes to misread mRNA. Streptomycin is an antibiotic that inhibits both Gram-positive and Gram-negative bacteria, and is therefore a useful broad-spectrum antibiotic.",
            "score": 83.62192249298096
        },
        {
            "docid": "25399827_5",
            "document": "Totarol . Table 1. Antibacterial activity of (+)-totarol against microorganisms Although (+)-totarol exhibits antimicrobial properties, the mode of action is unclear and various methods of inhibitory action have been proposed. In \"Staphylococcus aureus\" strains resistant to penicillin via creation of penicillin binding protein 2\u2019 (PBP2\u2019), (+)-totarol may inhibit the synthesis of PBP2\u2019. (+)-Totarol may inhibit effluxing \"Staphylococcus aureus\" strains through inhibition of MsrA, although it is unclear if MsrA is an efflux pump. (+)-Totarol may also gain its antibacterial properties by inhibiting bacterial respiratory transport but this is very unlikely because (+)-totarol is also effective against anaerobic organisms. Recently (+)-totarol was also hypothesized to inhibit gram-positive and acid-fast bacteria via inhibition of FtsZ protein, which forms the Z-ring, a polymer necessary for efficient bacterial cell cytokinesis.",
            "score": 83.64434015750885
        },
        {
            "docid": "14350666_4",
            "document": "Prokaryotic cytoskeleton . Despite this functional similarity to actin, FtsZ is homologous to eukaryal tubulin. Although comparison of the primary structures of FtsZ and tubulin reveal a weak relationship, their 3-dimensional structures are remarkably similar. Furthermore, like tubulin, monomeric FtsZ is bound to GTP and polymerizes with other FtsZ monomers with the hydrolysis of GTP in a mechanism similar to tubulin dimerization. Since FtsZ is essential for cell division in bacteria, this protein is a target for the design of new antibiotics. There currently exist several models and mechanisms that regulate Z-ring formation, but these mechanisms depend on the species. Several rod shaped species, including \"Escherichia coli\" and \"Caulobacter crescentus\", use one or more inhibitors of FtsZ assembly that form a bipolar gradient in the cell, enhancing polymerization of FtsZ at the cell center. One of these gradient-forming systems consists of MinCDE proteins (see below).",
            "score": 81.38895797729492
        },
        {
            "docid": "14248130_4",
            "document": "Antimicrobial pharmacodynamics . The post antibiotic effect (PAE) is defined as persistent suppression of bacterial growth after a brief exposure (1 or 2 hours) of bacteria to an antibiotic even in the absence of host defense mechanisms. Factors that affect the duration of the post antibiotic effect include duration of antibiotic exposure, bacterial species, culture medium and class of antibiotic. It has been suggested that an alteration of DNA function is possibly responsible for post antibiotic effect following the observation that most inhibitors of protein and nucleic acid synthesis (aminoglycosides, fluoroquinolones, tetracyclines, clindamycin, certain newer macrolides/ketolides, and rifampicin and rifabutin) induce long-term PAE against susceptible bacteria. Theoretically, the ability of an antibiotic to induce a PAE is an attractive property of an antibiotic since antibiotic concentrations could fall below the MIC for the bacterium yet retain their effectiveness in their ability to suppress the growth. Therefore, an antibiotic with PAE would require less frequent administration and it could improve patient adherence with regard to pharmacotherapy. Proposed mechanisms include (1) slow recovery after reversible nonlethal damage to cell structures; (2) persistence of the drug at a binding site or within the periplasmic space; and (3) the need to synthesize new enzymes before growth can resume. Most antimicrobials possess significant in vitro PAEs (\u2265 1.5 hours) against susceptible gram-positive cocci . Antimicrobials with significant PAEs against susceptible gram-negative bacilli are limited to carbapenems and agents that inhibit protein or DNA synthesis.",
            "score": 73.79252898693085
        },
        {
            "docid": "31776829_3",
            "document": "Hsp90 inhibitor . Among heat shock proteins the focus on HSP90 has increased due to its involvement in several cellular phenomena and more importantly in disease progression. HSP90 keeps the death proteins in an apoptosis resistant state by direct association. Its wide range of functions results from the ability of HSP90 to chaperone several client proteins that play a central pathogenic role in human diseases including cancer, neurodegenerative diseases and viral infection. Geldanamycin directly binds to the ATP-binding pocket in the N-terminal domain of Hsp90 and, hence, blocks the binding of nucleotides to Hsp90. Analysis of the effects of Geldanamycin on steroid receptor activation indicates that the antibiotic blocks the chaperone cycle at the intermediate complex, preventing the release of the receptor from Hsp90 and, eventually, resulting in its degradation. Ewing\u2019s sarcoma shows several deregulated autocrine loops mediating cell survival and proliferation. So their blockade is a promising therapeutic approach. Proteosome analysis revealed that Hsp90 is differentially expressed between ewing\u2019s sarcoma cell lines, sensitive and resistant to specific IGF1R/KIT inhibitors. The in vitro IGF1R/KIT pathway blockade on ewing\u2019s sarcoma cell lines and classified ewing\u2019s sarcoma cell lines as resistant and sensitive to blockade of pathway. Inhibition of Hsp90 with 17AAG and siRNA resulted in reduction of cell lines growth and survival. The inhibition of Hsp90 causes the proteosomal destruction of client proteins- Akt, KIT and IGF1R. This effect could be due to precluding physical contact between client proteins and Hsp90. So since the molecular chaperones are overexpressed in a wide variety of cancer cells and in virally transformed cells, inhibiting the function of these chaperones is essential to controlling cancer cells, as this would affect the activity of signaling proteins. The availability of drugs that can specifically target Hsp90 and inhibit its function, resulting in the depletion of client proteins, has made Hsp90 a novel and exciting target for cancer therapy.",
            "score": 76.9929358959198
        },
        {
            "docid": "19372852_8",
            "document": "MecA (gene) . Penecillin, its derivatives and methicilin, are beta-lactams that all work by disrupting the mechanical structure of the bacterial cell wall by reacting with the cell wall forming penicillin-binding protein family (PBP 1,2, 3 and 4), causing the cytoplasm to leak and the cell to die. However, the mecA gene codes for PBP2a, that has a lower affinity for antibiotic drugs, which keeps the structural integrity of the cell wall, preventing cell death. The synthesis of the bacterial cell wall in \"S. aureus\" is dependent on transglycosylation, to form linear polymer of sugar monomers, and transpeptidation, to form an interlinking peptides to strengthen the newly developed cell wall. PBPs have a transpeptidase domain, but transglycosylation was thought to only be carried out by monofunctional enzymes, however PBP2 has domains to carry out both essential processes. When antibiotics are introduced to the medium, they bind to the transpetidation domain and inhibit the ability of PBPs to cross-link muropeptides therefore preventing the formation of stable cell wall. but in a cooperative action, PBP2a lacks the proper receptor for the antibiotics, continuing the transpeptidation, preventing the breakdown of the cell wall. The functionality of PBP2a is dependent on two structural factors on the cell wall of \"S. aureus.\" First, there in order for PBP2a to properly fit onto the cell wall, to continue transpeptidation, requires proper amino acid residues, specifically a pentaglycine residue and an amidated glutamate residue. Furthermore, PBP2a has an effective transpeptidase activity, but lacks a transglycosylation domain of PBP2, which builds the backbone of the cell wall with polysaccharide monomers, and so PBP2a must rely on PBP2 to continue this process. The latter of these factors is an enzymatic reaction that can be targeted to improve the ability of beta-lactams to prevent cell wall synthesis in resistant \"S.\" aureus. Identification of genetic inhibitors of glycosylases involved in the cell wall synthesis, and modulating the expression of these inhibitors can resensitize these previously resistant bacteria to beta-lactam treatment. for example, Epicatechin gallate, a compound found in green tea, has shown signs of lowering the resistance to beta-lactams, to the point where oxacillin becomes effective to inhibit the formation of the cell wall, by inhibiting PBP2 and PBP2a.",
            "score": 74.83883333206177
        },
        {
            "docid": "44976065_5",
            "document": "NovoBiotic Pharmaceuticals . NovoBiotic Pharmaceuticals owns the patent rights to teixobactin, an antibiotic that has been shown to be active against pathogenic Gram-positive bacteria that have developed resistance to available approved antibiotics. The discovery and characterization of the compound was reported in 2015 in a collaboration between NovoBiotic, Northeastern University (Boston MA), University of Bonn (Germany) and Selcia Ltd. (UK). Teixobactin is believed to be more robust against mutation of the target pathogens because of its unusual antibiotic mechanism. Rather than binding to relatively mutable proteins in the bacterial cells, it binds to less mutable fatty molecules that are essential cell wall precursors.",
            "score": 65.54542803764343
        },
        {
            "docid": "4152874_7",
            "document": "Penicillin binding proteins . There has been a great deal of research into PBPs because of their role in antibiotics and resistance. Bacterial cell wall synthesis and the role of PBPs in its synthesis is a very good target for drugs of selective toxicity because the metabolic pathways and enzymes are unique to bacteria. Resistance to antibiotics has come about through overproduction of PBPs and formation of PBPs that have low affinity for penicillins (among other mechanisms such as lactamase production). Research on PBPs has led to the discovery of new semi-synthetic \u03b2-lactams, wherein altering the side-chains on the original penicillin molecule has increased the affinity of PBPs for penicillin, and, thus, increased effectiveness in bacteria with developing resistance.",
            "score": 63.22872757911682
        },
        {
            "docid": "42911578_4",
            "document": "Acyldepsipeptide antibiotics . ADEP antibiotics can be used to defeat resistant bacterial infections. They bind to ClpP and allow the protease to degrade proteins without the help of an ATPase. ADEP4/ClpP complexes target primarily newly formed proteins, and FtsZ which allows cell division. ClpP active form is a tetradecamer composed of two heptamers to which 14 ADEPs bind to. ADEPs bind in the cavities formed by two ClpP monomers. Their binding site is composed of hydrophobic residues and corresponds to the binding sites of ClpP ATPases. Upon binding, a series of secondary structures shifts occur from the outer region to the center of ClpP. This puts the flexible N-terminal \u03b2-loop, into a disordered state. The \u03b2-loops normally form a gate above the proteolytic channel and prevent proteins from randomly passing through. They are critical for ClpP interaction with its substrate and ATPases. When ADEP binds, the \u03b2-loops shift outward and this is accompanied by the shifts of two \u03b1-helices (\u03b11 and \u03b12), four \u03b2-strands (\u03b21, \u03b22, \u03b23 and \u03b25) and other loops which lead to the opening of the ClpP pore. In summary, ADEP4 deregulates ClpP function and changes it from a closed state to an open one. At this point its specific proteolytic activity becomes a less controlled process, with the destruction of proteins that are around in the targeted cell.",
            "score": 68.46965515613556
        },
        {
            "docid": "31776829_4",
            "document": "Hsp90 inhibitor . The current HSP90 inhibitors are developed from geldanamycin and radicicol which are the natural product inhibitors and are starting point for new approach.  HSP 90 is required for ATP dependent refolding of denatured or unfolded proteins and for the conformational maturation of a subset of proteins involved in the response of cells to extracellular signals. These include steroid receptors Raf \u2013 1, Akt, Met and Her 2. HSP90 has conserved unique pocket in N terminal region. It binds ATP & ADP and has weak ATPase activity. This suggests that site acts as nucleotide or nucleotide ratio sensor. It is observed that nucleotides adopt unique C shaped bent shape when binding to this pocket. This is particularly unusual as nucleotides never adopt shape change in high affinity ATP/ADP sites. This also indicates that drugs that are developed should also have potential to adopt unique C shape conformation in order to bind the unique pocket. The rationale for this unusual need i.e. to bend the structure, is based on thermo dynamical fact that the molecule which needs minimum structural changes to go from unbound to bound state should not pay much entropic penalties and binding would be reflected by enthalpic factors. Geldanamycin and radicicol tightly bind to this pocket and prevent the release of protein from chaperone complex. Thus the protein cannot achieve native conformation and is degraded by proteosome. Addition of such inhibitor causes proteosomal degradation of signaling proteins like steroid receptors, Raf kinase and Akt. Geldanamycin and radicicol also inhibit mutated protein in cancer cells like P53, Vsrc, BCR \u2013 ABL. It is worth to note that the normal counterparts are not inhibited. Geldanamycin is an effective HSP90 inhibitor still it cannot be used in vivo because of its high toxicity and liver damage ability. The speculation is that the benzoquinone functional group is responsible. The semi-synthetic derivative 17 AAG, with lower toxicity but same potency as geldanamycin is developed and is currently under clinical trials.",
            "score": 66.69910526275635
        },
        {
            "docid": "5464960_28",
            "document": "Enzyme inhibitor . In drug design it is important to consider the concentrations of substrates to which the target enzymes are exposed. For example, some protein kinase inhibitors have chemical structures that are similar to adenosine triphosphate, one of the substrates of these enzymes. However, drugs that are simple competitive inhibitors will have to compete with the high concentrations of ATP in the cell. Protein kinases can also be inhibited by competition at the binding sites where the kinases interact with their substrate proteins, and most proteins are present inside cells at concentrations much lower than the concentration of ATP. As a consequence, if two protein kinase inhibitors both bind in the active site with similar affinity, but only one has to compete with ATP, then the competitive inhibitor at the protein-binding site will inhibit the enzyme more effectively.",
            "score": 64.79882717132568
        },
        {
            "docid": "22519313_18",
            "document": "Cell surface receptor . Through methods such as X-ray crystallography and NMR spectroscopy, the information about 3D structures of target molecules has increased dramatically, and so has structural information about the ligands. This drives rapid development of structure-based drug design. Some of these new drugs target membrane receptors. Current approaches to structure-based drug design can be divided into two categories. The first category is about determining ligands for a given receptor. This is usually accomplished through database queries, biophysical simulations, and the construction of chemical libraries. In each case, a large number of potential ligand molecules are screened to find those fitting the binding pocket of the receptor. This approach is usually referred to as ligand-based drug design. The key advantage of searching a database is that it saves time and power to obtain new effective compounds. Another approach of structure-based drug design is about combinatorially mapping ligands, which is referred to as receptor-based drug design. In this case, ligand molecules are engineered within the constraints of a binding pocket by assembling small pieces in a stepwise manner. These pieces can be either atoms or molecules. The key advantage of such a method is that novel structures can be discovered.",
            "score": 63.29871225357056
        },
        {
            "docid": "45582346_10",
            "document": "Type VI secretion system . A wide range of Gram-negative bacteria have been shown to have antibacterial T6SSs, including opportunistic pathogens such as \"Pseudomonas aeruginosa\", obligate commensal species that inhabit the human gut (\"Bacteroides\" spp.), and plant-associated bacteria such as \"Agrobacterium tumefaciens\". These systems exert antibacterial activity via the function of their secreted substrates. All characterized bacterial-targeting T6SS proteins act as toxins, either by killing or preventing the growth of target cells. The mechanisms of toxicity toward target cells exhibited by T6SS substrates are diverse, but typically involve targeting of highly conserved bacterial structures, including degradation of the cell wall through amidase or glycohydrolase activity, disruption of cell membranes through lipase activity or pore formation, cleavage of DNA, and degradation of the essential metabolite NAD+. T6SS-positive bacterial species prevent T6SS-mediated intoxication towards self and kin cells by producing immunity proteins specific to each secreted toxin. The immunity proteins function by binding to the toxin proteins, often at their active site, thereby blocking their activity.",
            "score": 55.95400357246399
        },
        {
            "docid": "14087410_13",
            "document": "Heat shock protein 90kDa alpha (cytosolic), member A1 . Hsp90 is exploited by cancer cells to support activated oncoproteins, including many kinases and transcription factors. These clients are often mutated, amplified or translocated in malignancy, and Hsp90 works to buffer these cellular stresses induced by malignant transformation. Inhibition of Hsp90 leads to the degradation or instability of many of its client proteins. Thus, Hsp90 has become an attractive target for cancer therapy. As with all ATPases, ATP binding and hydrolysis is essential for the chaperoning function of Hsp90 in vivo. Hsp90 inhibitors interfere with this cycle at its early stages by replacing ATP, leading to the regulated ubiquitination and proteasome-mediated degradation of most client proteins. As such, the nucleotide binding pocket remains that most amenable to inhibitor generation. To date, there are 23 active Hsp90 inhibitor oncology trials, and 13 HSP90 inhibitors are currently undergoing clinical evaluation in cancer patients, 10 of which have entered the clinic in the past few years. While the N-terminal nucleotide-binding pocket of Hsp90 is most widely studied and thus targeted, recent studies have suggested that a second ATP-binding site is located in the Hsp90 C-terminus. Targeting of this region has resulted in specific reduced Hsp90-hormone interactions and has been shown to influence Hsp90 nucleotide binding. Although none of the C-terminal Hsp90 inhibitors have yet to enter the clinic, the use of both N- and C-terminal Hsp90 inhibitors in combination represents an exciting new strategy for chemotherapy. Although many of the afore-mentioned inhibitors share the same Hsp90 binding site (either N- or C-terminal), it has been shown that some of these drugs preferentially access distinct Hsp90 populations, which are differentiated by the extent of their post-translational modification. Though no published inhibitor has yet to distinguish between Hsp90A and Hsp90B, a recent study has shown that phosphorylation of a particular residue in the Hsp90 N-terminus can provide isoform specificity to inhibitor binding., thus providing an additional level of regulation for optimal Hsp90 targeting.",
            "score": 51.988754987716675
        },
        {
            "docid": "188688_44",
            "document": "Active site . Identification of active sites is crucial in the process of drug discovery. The 3-D structure of the enzyme is analysed to identify active sites and design drugs which can fit into them. Proteolytic enzymes are targets for some drugs, such as protease inhibitors, which include drugs against AIDS and hypertension. These protease inhibitors bind to an enzyme's active site and block interaction with natural substrates. An important factor in drug design is the strength of binding between the active site and an enzyme inhibitor. If the enzyme found in bacteria is significantly different from the human enzyme then an inhibitor can be designed against that particular bacterium without harming the human enzyme. If one kind of enzyme is only present in one kind of organism, its inhibitor can be used to specifically wipe them out.",
            "score": 48.63418197631836
        },
        {
            "docid": "44180583_12",
            "document": "Bacterial Leucine Transporter . LeuT was first crystallized by the New York Consortium on Membrane Protein Structure (NYCOMPS) and other researchers from the bacteria species \"Aquifex aeolicus\" with the aim of understanding the underlying molecular mechanisms of antidepressants\u2019 binding to their target proteins, the neurotransmitter transporters. As these proteins have proven difficult to be crystallized, LeuT emerged as a promising homologue for the docking of these drugs.",
            "score": 61.717217445373535
        },
        {
            "docid": "1686272_40",
            "document": "Chemical biology . Through the use of a number of classes of small molecule modulators of protein kinases, chemical biologists have been able to gain a better understanding of the effects of protein phosphorylation. For example, nonselective and selective kinase inhibitors, such as a class of pyridinylimidazole compounds described by Wilson, et al., are potent inhibitors useful in the dissection of MAP kinase signaling pathways. These pyridinylimidazole compounds function by targeting the ATP binding pocket. Although this approach, as well as related approaches, with slight modifications, has proven effective in a number of cases, these compounds lack adequate specificity for more general applications. Another class of compounds, mechanism-based inhibitors, combines detailed knowledge of the chemical mechanism of kinase action with previously utilized inhibition motifs. For example, Parang, et al. describe the development of a \"bisubstrate analog\" that inhibits kinase action by binding both the conserved ATP binding pocket and a protein/peptide recognition site on the specific kinase. While there is no published in vivo data on compounds of this type, the structural data acquired from in vitro studies have expanded the current understanding of how a number of important kinases recognize target substrates. Interestingly, many research groups utilized ATP analogs as a chemical probe to study kinases and identify their substrates.",
            "score": 62.02681803703308
        },
        {
            "docid": "413102_22",
            "document": "Folding@home . Chemical activity occurs along a protein's active site. Traditional drug design methods involve tightly binding to this site and blocking its activity, under the assumption that the target protein exists in one rigid structure. However, this approach works for approximately only 15% of all proteins. Proteins contain allosteric sites which, when bound to by small molecules, can alter a protein's conformation and ultimately affect the protein's activity. These sites are attractive drug targets, but locating them is very computationally costly. In 2012, Folding@home and MSMs were used to identify allosteric sites in three medically relevant proteins: beta-lactamase, interleukin-2, and RNase H.",
            "score": 52.37801122665405
        },
        {
            "docid": "42911578_3",
            "document": "Acyldepsipeptide antibiotics . The potential role of ADEPs in combating antibiotic drug resistance is postulated due to their novel mode of action that other antibiotics are not known to use, activation of casein lytic protease (ClpP) which is an important bacterial protease. Most antibiotics work through inhibitory processes to establish cell death, while ADEPs actually work through activation of the protease to cause uncontrolled protein degradation, inhibition of cell division, and subsequent cell death. They largely affect Gram-positive bacteria and could be of great use to target antibiotic resistant microbes such as methicillin-resistant \"Staphylococcus aureus\" (MRSA), penicillin-resistant \"Streptococcus pneumonia\" (PRSP), \"Mycobacterium tuberculosis\", and others. Despite the potential use of ADEP, possible resistance has been examined in certain species.",
            "score": 90.6923199892044
        },
        {
            "docid": "1805_16",
            "document": "Antibiotic . Antibiotics are commonly classified based on their mechanism of action, chemical structure, or spectrum of activity. Most target bacterial functions or growth processes. Those that target the bacterial cell wall (penicillins and cephalosporins) or the cell membrane (polymyxins), or interfere with essential bacterial enzymes (rifamycins, lipiarmycins, quinolones, and sulfonamides) have bactericidal activities. Protein synthesis inhibitors (macrolides, lincosamides and tetracyclines) are usually bacteriostatic (with the exception of bactericidal aminoglycosides). Further categorization is based on their target specificity. \"Narrow-spectrum\" antibiotics target specific types of bacteria, such as gram-negative or gram-positive, whereas broad-spectrum antibiotics affect a wide range of bacteria. Following a 40-year break in discovering new classes of antibacterial compounds, four new classes of antibiotics have been brought into clinical use in the late 2000s and early 2010s: cyclic lipopeptides (such as daptomycin), glycylcyclines (such as tigecycline), oxazolidinones (such as linezolid), and lipiarmycins (such as fidaxomicin).",
            "score": 55.99477696418762
        },
        {
            "docid": "1914_3",
            "document": "Antimicrobial resistance . Resistance arises through one of three mechanisms: natural resistance in certain types of bacteria, genetic mutation, or by one species acquiring resistance from another. All classes of microbes can develop resistance. Fungi develop antifungal resistance. Viruses develop antiviral resistance. Protozoa develop antiprotozoal resistance, and bacteria develop antibiotic resistance. Resistance can appear spontaneously because of random mutations. However, extended use of antimicrobials appears to encourage mutations which can render antimicrobials ineffective. Preventive measures include only using antibiotics when needed, thereby stopping misuse of antibiotics or antimicrobials. Narrow-spectrum antibiotics are preferred over broad-spectrum antibiotics when possible, as effectively and accurately targeting specific organisms is less likely to cause resistance. For people who take these medications at home, education about proper use is essential. Health care providers can minimize spread of resistant infections by use of proper sanitation and hygiene, including handwashing and disinfecting between patients, and should encourage the same of the patient, visitors, and family members. Rising drug resistance is caused mainly by use of antimicrobials in humans and other animals, and spread of resistant strains between the two. Growing resistance has also been linked to dumping of inadequately treated effluents from the pharmaceutical industry, especially in countries where bulk drugs are manufactured. Antibiotics increase selective pressure in bacterial populations, causing vulnerable bacteria to die; this increases the percentage of resistant bacteria which continue growing. Even at very low levels of antibiotic, resistant bacteria can have a growth advantage and grow faster than vulnerable bacteria. With resistance to antibiotics becoming more common there is greater need for alternative treatments. Calls for new antibiotic therapies have been issued, but new drug development is becoming rarer.",
            "score": 71.56131279468536
        },
        {
            "docid": "5464960_40",
            "document": "Enzyme inhibitor . More recently, an alternative approach has been applied: rational drug design uses the three-dimensional structure of an enzyme's active site to predict which molecules might be inhibitors. These predictions are then tested and one of these tested compounds may be a novel inhibitor. This new inhibitor is then used to try to obtain a structure of the enzyme in an inhibitor/enzyme complex to show how the molecule is binding to the active site, allowing changes to be made to the inhibitor to try to optimise binding. This test and improve cycle is then repeated until a sufficiently potent inhibitor is produced. Computer-based methods of predicting the affinity of an inhibitor for an enzyme are also being developed, such as molecular docking and molecular mechanics.",
            "score": 66.22550642490387
        },
        {
            "docid": "579414_4",
            "document": "Drug design . A biomolecular target (most commonly a protein or nucleic acid) is a key molecule involved in a particular metabolic or signaling pathway that is associated with a specific disease condition or pathology or to the infectivity or survival of a microbial pathogen. Potential drug targets are not necessarily disease causing but must by definition be disease modifying. In some cases, small molecules will be designed to enhance or inhibit the target function in the specific disease modifying pathway. Small molecules (for example receptor agonists, antagonists, inverse agonists, or modulators; enzyme activators or inhibitors; or ion channel openers or blockers) will be designed that are complementary to the binding site of target. Small molecules (drugs) can be designed so as not to affect any other important \"off-target\" molecules (often referred to as antitargets) since drug interactions with off-target molecules may lead to undesirable side effects. Due to similarities in binding sites, closely related targets identified through sequence homology have the highest chance of cross reactivity and hence highest side effect potential.",
            "score": 68.10045075416565
        },
        {
            "docid": "10155189_8",
            "document": "STAT5 . Indirect inhibition targets kinases associated with STAT5, or targets proteases that carry out terminal truncation of proteins. Different inhibitors have been designed to target different kinases: Direct inhibition of STAT5 activity makes use of small molecule inhibitors that prevent STAT5 from properly binding to DNA, or prevent proper dimerization. The inhibiting of DNA binding utilizes RNA interference, antisense oligodeoxynucleotide, and short hairpin RNA. The inhibition of proper dimerization, on the other hand, is brought about by the use of small molecules that target the SH2 domain. Recent work on drug development in the latter field have proved particularly effective.",
            "score": 62.30897235870361
        },
        {
            "docid": "24664397_16",
            "document": "Discovery and development of non-nucleoside reverse-transcriptase inhibitors . The development of effective anti-HIV drugs is difficult due to wide variations in nucleotide and amino acid sequences. The perfect anti-HIV drug chemical should be effective against drug resistance mutation. Understanding the target RT enzyme and its structure, mechanism of drug action and the consequence of drug resistance mutations provide useful information which can be helpful to design more effective NNRTIs. The RT enzyme can undergo change due to mutations that can disturb NNRTI binding.",
            "score": 50.665294766426086
        }
    ],
    "r": [
        {
            "docid": "42911578_3",
            "document": "Acyldepsipeptide antibiotics . The potential role of ADEPs in combating antibiotic drug resistance is postulated due to their novel mode of action that other antibiotics are not known to use, activation of casein lytic protease (ClpP) which is an important bacterial protease. Most antibiotics work through inhibitory processes to establish cell death, while ADEPs actually work through activation of the protease to cause uncontrolled protein degradation, inhibition of cell division, and subsequent cell death. They largely affect Gram-positive bacteria and could be of great use to target antibiotic resistant microbes such as methicillin-resistant \"Staphylococcus aureus\" (MRSA), penicillin-resistant \"Streptococcus pneumonia\" (PRSP), \"Mycobacterium tuberculosis\", and others. Despite the potential use of ADEP, possible resistance has been examined in certain species.",
            "score": 90.69232177734375
        },
        {
            "docid": "25399827_5",
            "document": "Totarol . Table 1. Antibacterial activity of (+)-totarol against microorganisms Although (+)-totarol exhibits antimicrobial properties, the mode of action is unclear and various methods of inhibitory action have been proposed. In \"Staphylococcus aureus\" strains resistant to penicillin via creation of penicillin binding protein 2\u2019 (PBP2\u2019), (+)-totarol may inhibit the synthesis of PBP2\u2019. (+)-Totarol may inhibit effluxing \"Staphylococcus aureus\" strains through inhibition of MsrA, although it is unclear if MsrA is an efflux pump. (+)-Totarol may also gain its antibacterial properties by inhibiting bacterial respiratory transport but this is very unlikely because (+)-totarol is also effective against anaerobic organisms. Recently (+)-totarol was also hypothesized to inhibit gram-positive and acid-fast bacteria via inhibition of FtsZ protein, which forms the Z-ring, a polymer necessary for efficient bacterial cell cytokinesis.",
            "score": 83.64434051513672
        },
        {
            "docid": "209023_12",
            "document": "Streptomycin . Streptomycin is a protein synthesis inhibitor. It binds to the small 16S rRNA of the 30S subunit of the bacterial ribosome, interfering with the binding of formyl-methionyl-tRNA to the 30S subunit. This leads to codon misreading, eventual inhibition of protein synthesis and ultimately death of microbial cells through mechanisms that are still not understood. Speculation on this mechanism indicates that the binding of the molecule to the 30S subunit interferes with 50S subunit association with the mRNA strand. This results in an unstable ribosomal-mRNA complex, leading to a frameshift mutation and defective protein synthesis; leading to cell death. Humans have ribosomes which are structurally different from those in bacteria, so the drug does not have this effect in human cells. At low concentrations, however, streptomycin only inhibits growth of the bacteria by inducing prokaryotic ribosomes to misread mRNA. Streptomycin is an antibiotic that inhibits both Gram-positive and Gram-negative bacteria, and is therefore a useful broad-spectrum antibiotic.",
            "score": 83.62191772460938
        },
        {
            "docid": "2065768_4",
            "document": "Antimicrobial peptides . The modes of action by which antimicrobial peptides kill microbes are varied, and may differ for different bacterial species. Some antimicrobial peptides kill both bacteria and fungi, e.g., psoriasin kills \"E. coli\" and several filamentous fungi. The cytoplasmic membrane is a frequent target, but peptides may also interfere with DNA and protein synthesis, protein folding, and cell wall synthesis. The initial contact between the peptide and the target organism is electrostatic, as most bacterial surfaces are anionic, or hydrophobic, such as in the antimicrobial peptide Piscidin. Their amino acid composition, amphipathicity, cationic charge and size allow them to attach to and insert into membrane bilayers to form pores by \u2018barrel-stave\u2019, \u2018carpet\u2019 or \u2018toroidal-pore\u2019 mechanisms. Alternately, they may penetrate into the cell to bind intracellular molecules which are crucial to cell living. Intracellular binding models includes inhibition of cell wall synthesis, alteration of the cytoplasmic membrane, activation of autolysin, inhibition of DNA, RNA, and protein synthesis, and inhibition of certain enzymes. However, in many cases, the exact mechanism of killing is not known. One emerging technique for the study of such mechanisms is dual polarisation interferometry. In contrast to many conventional antibiotics these peptides appear to be bactericidal instead of bacteriostatic. In general the antimicrobial activity of these peptides is determined by measuring the minimal inhibitory concentration (MIC), which is the lowest concentration of drug that inhibits bacterial growth.",
            "score": 83.00950622558594
        },
        {
            "docid": "14350666_4",
            "document": "Prokaryotic cytoskeleton . Despite this functional similarity to actin, FtsZ is homologous to eukaryal tubulin. Although comparison of the primary structures of FtsZ and tubulin reveal a weak relationship, their 3-dimensional structures are remarkably similar. Furthermore, like tubulin, monomeric FtsZ is bound to GTP and polymerizes with other FtsZ monomers with the hydrolysis of GTP in a mechanism similar to tubulin dimerization. Since FtsZ is essential for cell division in bacteria, this protein is a target for the design of new antibiotics. There currently exist several models and mechanisms that regulate Z-ring formation, but these mechanisms depend on the species. Several rod shaped species, including \"Escherichia coli\" and \"Caulobacter crescentus\", use one or more inhibitors of FtsZ assembly that form a bipolar gradient in the cell, enhancing polymerization of FtsZ at the cell center. One of these gradient-forming systems consists of MinCDE proteins (see below).",
            "score": 81.38896179199219
        },
        {
            "docid": "39458335_4",
            "document": "PageRank algorithm in biochemistry . The clinical use of most antibiotics result in a mutation of the pathogen organism leading to their resistance against the drug. Therefore, development of new drugs is always needed. A potential first step in developing new drugs against currently threatening diseases (e.g. tubercolosis) is to find new drug targets in the causative agent of the disease, i.e. the pathogen microorganism, let it be either a bacterium, or a protozoan parasite. After finding the target protein in the bacterium (or protozoan parasite), one could design small molecular drug compounds that bind to the protein and inhibit it.",
            "score": 80.85916900634766
        },
        {
            "docid": "42911578_11",
            "document": "Acyldepsipeptide antibiotics . In 2011, P. Sass and co-workers performed a research focusing in the interaction and function of ADEPs and ClpP. They induced ADEP into \"Bacillus subtilis\", \"Staphylococcus aureus\" and \"Streptococcus pneumoniae\" to identify how ADEP leads to the death of bacteria. The results demonstrated that ADEP is perturbing bacterial cell division. To identify the reason why ADEP inhibited cell division, researchers monitored septum formation and nucleoid segregation in ADEP \"B. subtilis\" and ADEP \"S. aureus\". The \"S. aureus\" and \"B. subtilis\" samples gave equivalent results. This part showed the importance of wild type of ClpP and inhibition of septum formation is by direct interference of ADEP with the cell division components. Localization studies by GFP-labeled cell divisions proteins demonstrated that ADEP causes delocalization of Ftsz and inhibition of Z-Ring assembly in both species. The impact of ADEP in \u2206clpX mutant indicated that ADEP is affecting cell division and that it also inhibits Z-ring assembly. Finally researchers repeat the experiment with \u2206ClpP mutant to confirm that the presence of ADEP decreases abundance of FtsZ through ClpP degradation.",
            "score": 80.77190399169922
        },
        {
            "docid": "42243985_4",
            "document": "MinC . MinC is known to dimerize and functions as an FtsZ protein inhibitor, antagonizing its structure assembly when in a high enough concentration. The protein has the ability to disassemble the ZapA, ZapB and ZipA proteins which preferentially bind to the FtsZ scaffold protein and which are needed to initiate cell division. Concentrations of MinC are lowest at the mid-zone of bacterial cells, thereby permitting septum formation and scaffold assembly at the cellular mid-zone since the Min System proteins (MinCDE) are lowest in concentration in this region, alleviating the physical inhibition on the proteins required to initiate division.",
            "score": 79.694580078125
        },
        {
            "docid": "1491100_29",
            "document": "Flavin adenine dinucleotide . New design of anti-bacterial medications is of continuing importance in scientific research as bacterial antibiotic resistance to common antibiotics increases. A specific metabolic protein that uses FAD (Complex II) is vital for bacterial virulence, and so targeting FAD synthesis or creating FAD analogs could be a useful area of investigation. Already, scientists have determined the two structures FAD usually assumes once bound: either an extended or a butterfly conformation, in which the molecule essentially folds in half, resulting in the stacking of the adenine and isoalloxazine rings. FAD imitators that are able to bind in a similar manner but do not permit protein function could be useful mechanisms of inhibiting bacterial infection. Alternatively, drugs blocking FAD synthesis could achieve the same goal; this is especially intriguing because human and bacterial FAD synthesis relies on very different enzymes, meaning that a drug made to target bacterial FAD synthase would be unlikely to interfere with the human FAD synthase enzymes.",
            "score": 77.94204711914062
        },
        {
            "docid": "2936433_11",
            "document": "Cefotaxime . Cefotaxime is a \u03b2-lactam antibiotic (which refers to the structural components of the drug molecule itself). As a class, \u03b2-lactams inhibit bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs). This inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) in the absence of cell wall assembly. Due to the mechanism of their attack on bacterial cell wall synthesis, \u03b2-lactams are considered to be bactericidal.",
            "score": 77.71172332763672
        },
        {
            "docid": "31776829_3",
            "document": "Hsp90 inhibitor . Among heat shock proteins the focus on HSP90 has increased due to its involvement in several cellular phenomena and more importantly in disease progression. HSP90 keeps the death proteins in an apoptosis resistant state by direct association. Its wide range of functions results from the ability of HSP90 to chaperone several client proteins that play a central pathogenic role in human diseases including cancer, neurodegenerative diseases and viral infection. Geldanamycin directly binds to the ATP-binding pocket in the N-terminal domain of Hsp90 and, hence, blocks the binding of nucleotides to Hsp90. Analysis of the effects of Geldanamycin on steroid receptor activation indicates that the antibiotic blocks the chaperone cycle at the intermediate complex, preventing the release of the receptor from Hsp90 and, eventually, resulting in its degradation. Ewing\u2019s sarcoma shows several deregulated autocrine loops mediating cell survival and proliferation. So their blockade is a promising therapeutic approach. Proteosome analysis revealed that Hsp90 is differentially expressed between ewing\u2019s sarcoma cell lines, sensitive and resistant to specific IGF1R/KIT inhibitors. The in vitro IGF1R/KIT pathway blockade on ewing\u2019s sarcoma cell lines and classified ewing\u2019s sarcoma cell lines as resistant and sensitive to blockade of pathway. Inhibition of Hsp90 with 17AAG and siRNA resulted in reduction of cell lines growth and survival. The inhibition of Hsp90 causes the proteosomal destruction of client proteins- Akt, KIT and IGF1R. This effect could be due to precluding physical contact between client proteins and Hsp90. So since the molecular chaperones are overexpressed in a wide variety of cancer cells and in virally transformed cells, inhibiting the function of these chaperones is essential to controlling cancer cells, as this would affect the activity of signaling proteins. The availability of drugs that can specifically target Hsp90 and inhibit its function, resulting in the depletion of client proteins, has made Hsp90 a novel and exciting target for cancer therapy.",
            "score": 76.99293518066406
        },
        {
            "docid": "205627_18",
            "document": "Drug resistance . For antibiotic resistance, which represents a widespread problem nowadays, drugs designed to block the mechanisms of bacterial antibiotic resistance are used. For example, bacterial resistance against beta-lactam antibiotics (such as penicillins and cephalosporins) can be circumvented by using antibiotics such as nafcillin that are not susceptible to destruction by certain beta-lactamases (the group of enzymes responsible for breaking down beta-lactams). Beta-lactam bacterial resistance can also be dealt with by administering beta-lactam antibiotics with drugs that block beta-lactamases such as clavulanic acid so that the antibiotics can work without getting destroyed by the bacteria first. Recently, researchers have recognized the need for new drugs that inhibit bacterial efflux pumps, which cause resistance to multiple antibiotics such as beta-lactams, quinolones, chloramphenicol, and trimethoprim by sending molecules of those antibiotics out of the bacterial cell. Sometimes a combination of different classes of antibiotics may be used synergistically; that is, they work together to effectively fight bacteria that may be resistant to one of the antibiotics alone.",
            "score": 75.91041564941406
        },
        {
            "docid": "57413297_2",
            "document": "Murepavadin . The host defense antimicrobial peptide protegrin I (PG-1), exhibits broad-spectrum antimicrobial activity and good activity against multi-drug resistant Gram-negative pathogens, with a mechanism consistent with membrane disruption via pore formation. However, PG-1 exhibits unfavorable drug properties and also exhibits significant hemolysis and, as such, has limited clinical use. PG-1 contains 18 amino acids and is ordered into an anti-parallel \u03b2-strand by two disulfide bridges. A fully synthetic cyclic peptide-like molecule containing a D-proline\u2013L-proline template grafted into a peptidomimetic scaffold to simulate and stabilize the beta hairpin conformation exhibited by PG-1 was used to generate a diverse library of peptidomimetic macrocycles which were screened for antibacterial activity. Variants in this 14-residue protein epitope mimetic (PEM) library such as the peptidomimetic L8-1 had an antimicrobial activity like that of PG-1 but with reduced hemolytic activity on human red blood cells. Iterative rounds of synthesis generated analogues with an increasingly potent and selective profile producing nanomolar range compounds specifically against Pseudomonas spp. at the expense of broad-spectrum activity. Final optimization led to the discovery of murepavadin, with remarkable Pseudomonas-specific activity \"in vitro\" and \"in vivo\" that has high plasma stability across species and is non-hemolytic at 100\u00a0\u00b5g/mL. Structure\u2013activity relationship (SAR) studies showed that aromatic side chains of Trp2 and Trp8 are very important for antibiotic activity, while NMR studies showed that these potent D-Pro-L-Pro antibiotic derivatives had a stable \u03b2- hairpin conformation in aqueous solution whereas related derivatives with the D-Pro-L-Pro template inverted to L-Pro-D-Pro, shows no stable hairpin conformation and the antimicrobial activity was lost, suggesting that the \u03b2-hairpin structure is crucial for interaction with the bacterial target. Murepavadin functions through a novel mechanism of action by binding to the lipopolysaccharide (LPS) transport protein D (LptD), an outer membrane protein involved in lipopolysaccharide biogenesis in Gram-negative bacteria. By binding to LptD, murepavadin inhibit the LPS transport function of LptD and causes lipopolysaccharide alterations in the outer membrane of the bacterium and, ultimately, cell death.",
            "score": 75.42142486572266
        },
        {
            "docid": "466746_17",
            "document": "Mycoplasma pneumoniae . The difficulty in eradicating \"Mycoplasma pneumoniae\" infections is due to the ability of the bacterium to persist within an individual, as well as the lack of cell wall in \"M. pneumoniae\", which renders multiple antibiotics directed at the bacterial cell wall ineffective in treating infections. \"M. pneumoniae\" therefore displays resistance to antimicrobials such as \u03b2-lactams, glycopeptides, sulfonamides, trimethoprim, polymixins, nalidixic acid, and rifampin. The majority of antibiotics used to treat \"M. pneumoniae\" infections are targeted at bacterial rRNA in ribosomal complexes, including macrolides, tetracycline, ketolides, and fluoroquinolone, many of which can be administered orally. Macrolides are capable of reducing hyperresponsiveness and protecting the epithelial lining from oxidative and structural damage, however they are capable only of inhibiting bacteria (bacteriostatic) and are not able to cause bacterial cell death. The most common macrolides used in the treatment of infected children in Japan are erythromycin and clarithromycin, which inhibit bacterial protein synthesis by binding 23S rRNA. Administration of antibiotics has been proven to reduce the longevity and intensity of \"M. pneumoniae\" infections in comparison to cases left untreated. Additionally, some high-dose steroid therapies have shown to reverse neurological effects in children with complicated infections. Antimicrobial drug resistance rates for \"Mycoplasma pneumoniae\" were determined in clinical specimens and isolates obtained during 2011\u20132012 in Ontario, Canada. Of 91 \"M. pneumoniae\" drug-resistant specimens, 11 (12.1%) carried nucleotide mutations associated with macrolide resistance in the 23S rRNA gene. None of the \"M. pneumoniae\" specimens were resistant to fluoroquinolones or tetracyclines.",
            "score": 74.86909484863281
        },
        {
            "docid": "19372852_8",
            "document": "MecA (gene) . Penecillin, its derivatives and methicilin, are beta-lactams that all work by disrupting the mechanical structure of the bacterial cell wall by reacting with the cell wall forming penicillin-binding protein family (PBP 1,2, 3 and 4), causing the cytoplasm to leak and the cell to die. However, the mecA gene codes for PBP2a, that has a lower affinity for antibiotic drugs, which keeps the structural integrity of the cell wall, preventing cell death. The synthesis of the bacterial cell wall in \"S. aureus\" is dependent on transglycosylation, to form linear polymer of sugar monomers, and transpeptidation, to form an interlinking peptides to strengthen the newly developed cell wall. PBPs have a transpeptidase domain, but transglycosylation was thought to only be carried out by monofunctional enzymes, however PBP2 has domains to carry out both essential processes. When antibiotics are introduced to the medium, they bind to the transpetidation domain and inhibit the ability of PBPs to cross-link muropeptides therefore preventing the formation of stable cell wall. but in a cooperative action, PBP2a lacks the proper receptor for the antibiotics, continuing the transpeptidation, preventing the breakdown of the cell wall. The functionality of PBP2a is dependent on two structural factors on the cell wall of \"S. aureus.\" First, there in order for PBP2a to properly fit onto the cell wall, to continue transpeptidation, requires proper amino acid residues, specifically a pentaglycine residue and an amidated glutamate residue. Furthermore, PBP2a has an effective transpeptidase activity, but lacks a transglycosylation domain of PBP2, which builds the backbone of the cell wall with polysaccharide monomers, and so PBP2a must rely on PBP2 to continue this process. The latter of these factors is an enzymatic reaction that can be targeted to improve the ability of beta-lactams to prevent cell wall synthesis in resistant \"S.\" aureus. Identification of genetic inhibitors of glycosylases involved in the cell wall synthesis, and modulating the expression of these inhibitors can resensitize these previously resistant bacteria to beta-lactam treatment. for example, Epicatechin gallate, a compound found in green tea, has shown signs of lowering the resistance to beta-lactams, to the point where oxacillin becomes effective to inhibit the formation of the cell wall, by inhibiting PBP2 and PBP2a.",
            "score": 74.83883666992188
        },
        {
            "docid": "1805_50",
            "document": "Antibiotic . Plants are an important source of antimicrobial compounds and traditional healers have long used plants to prevent or cure infectious diseases. There is a recent renewed interest into the use of natural products for the identification of new members of the 'antibiotic-ome' (defined as natural products with antibiotic activity), and their application in antibacterial drug discovery in the genomics era. Phytochemicals are the active biological component of plants and some phytochemicals including tannins, alkaloids, terpenoids and flavonoids possess antimicrobial activity. Some antioxidant dietary supplements also contain phytochemicals (polyphenols), such as grape seed extract, and demonstrate \"in vitro\" anti-bacterial properties. Phytochemicals are able to inhibit peptidoglycan synthesis, damage microbial membrane structures, modify bacterial membrane surface hydrophobicity and also modulate quorum-sensing. With increasing antibiotic resistance in recent years, the potential of new plant-derived antibiotics is under investigation.",
            "score": 74.24974060058594
        },
        {
            "docid": "424464_2",
            "document": "Linezolid . Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant \"Staphylococcus aureus\" (MRSA). The main uses are infections of the skin and pneumonia although it may be used for a variety of other infections including drug resistant tuberculosis. It is used either by injection into a vein or by mouth. Linezolid is a member of the oxazolidinone class of medications. When given for short periods, linezolid is a relatively safe antibiotic. It can be used in people of all ages and in people with liver disease or poor kidney function. Common side effects with short-term use include headache, diarrhea, rash, and nausea. Serious side effects may include serotonin syndrome, bone marrow suppression, and high blood lactate levels, particularly when used for more than two weeks. If used for longer periods it may cause nerve damage, including optic nerve damage, which may be irreversible. As a protein synthesis inhibitor, it affects the ability of bacteria to produce protein. This either stops growth or results in bacterial death. Although many antibiotics work this way, the exact mechanism of action of linezolid appears to be unique in that it blocks the start of protein production, rather than one of the later steps. As of 2014 bacterial resistance to linezolid has remained low. Linezolid was discovered in the mid 1990s and was approved for commercial use in 2000. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Linezolid is available as a generic medication. The wholesale cost in the developing world is about US$ 2.90 USD per day while that in the United States as of 2016 is about US$13.79 per day. It appears to be more cost-effective than alternatives such as vancomycin, mostly because of the ability to switch from intravenous use to administration by mouth sooner. The main use of linezolid is the treatment of severe infections caused by anaerobic Gram-positive bacteria that are resistant to other antibiotics; it should not be used against bacteria that are sensitive to drugs with a narrower spectrum of activity, such as penicillins and cephalosporins. In both the popular press and the scientific literature, linezolid has been called a \"reserve antibiotic\"\u2014one that should be used sparingly so that it will remain effective as a drug of last resort against potentially intractable infections.",
            "score": 73.8330307006836
        },
        {
            "docid": "14248130_4",
            "document": "Antimicrobial pharmacodynamics . The post antibiotic effect (PAE) is defined as persistent suppression of bacterial growth after a brief exposure (1 or 2 hours) of bacteria to an antibiotic even in the absence of host defense mechanisms. Factors that affect the duration of the post antibiotic effect include duration of antibiotic exposure, bacterial species, culture medium and class of antibiotic. It has been suggested that an alteration of DNA function is possibly responsible for post antibiotic effect following the observation that most inhibitors of protein and nucleic acid synthesis (aminoglycosides, fluoroquinolones, tetracyclines, clindamycin, certain newer macrolides/ketolides, and rifampicin and rifabutin) induce long-term PAE against susceptible bacteria. Theoretically, the ability of an antibiotic to induce a PAE is an attractive property of an antibiotic since antibiotic concentrations could fall below the MIC for the bacterium yet retain their effectiveness in their ability to suppress the growth. Therefore, an antibiotic with PAE would require less frequent administration and it could improve patient adherence with regard to pharmacotherapy. Proposed mechanisms include (1) slow recovery after reversible nonlethal damage to cell structures; (2) persistence of the drug at a binding site or within the periplasmic space; and (3) the need to synthesize new enzymes before growth can resume. Most antimicrobials possess significant in vitro PAEs (\u2265 1.5 hours) against susceptible gram-positive cocci . Antimicrobials with significant PAEs against susceptible gram-negative bacilli are limited to carbapenems and agents that inhibit protein or DNA synthesis.",
            "score": 73.79252624511719
        },
        {
            "docid": "31593256_4",
            "document": "Altechromone A . For thousands of years, humans have used endophytic species in traditional medicines. Since Louis Pasteur began investigating microbes, science has further revealed the potential benefits of these compounds. Researchers noted that this compound demonstrates both root growth promotion and inhibits bacterial production. Penicillin and other antibiotics effectively treated microbial infections. However, antibiotic misuse has resulted in resistance of pathogens to antimicrobial agents. Altechromone A could provide a source of antimocrobial agents that microbes have yet to develop a resistance to. In addition, the compound could possess anti-tumor capabilities thus yielding more potential medical applications.",
            "score": 73.67753601074219
        },
        {
            "docid": "501183_18",
            "document": "FtsZ . Like SulA, there are other mechanisms that prevent cell division that would result in disrupted genetic information sent to daughter cells. So far, two proteins have been identified in \"E. coli\" and \"B. subtilis\" that prevent division over the nucleoid region: Noc and SlmA. Noc gene knockouts result in cells that divide without respect to the nucleoid region, resulting in its asymmetrical partitioning between the daughter cells. The mechanism is not well understood, but thought to involve sequestration of FtsZ, preventing polymerization over the nucleoid region. The mechanism used by SlmA to inhibit FtsZ polymerization over the nucleoid is better understood, and uses two separate steps. One domain of SlmA binds to a FtsZ polymer, then a separate domain of SlmA severs the polymer . A similar mechanism is thought to be used by MinC, another inhibitor of FtsZ polymerization involved in positioning of the FtsZ ring.",
            "score": 73.60704803466797
        },
        {
            "docid": "44981660_7",
            "document": "Eleftheria terrae . \"E. terrae\"s production of teixobactin is prominent because recent tests have revealed that teixobactin binds differently than most normally used antibiotics which makes it harder for the bacteria being attacked to develop resistance. Experiments performed by Ling et al. have shown teixobactin is capable of binding to lipid precursors of peptidoglycan, which makes up part of bacterial cell walls. The results did not show any resistance to teixobactin in the organisms that were studied, including \"Staphylococcus aureus\" and \"Mycobacterium tuberculosis\". These findings indicate that teixobactin's target is not a protein, leading to the belief that the development of bacterial resistance to teixobactin is much less likely. These experiments also showed that teixobactin followed a similar mechanism of action as the antibiotic vancomycin that binds to the lipid II molecule in peptidoglycan precursors but, unlike vancomycin, teixobactin is capable of binding to modified lipid II molecules found in vancomycin resistant bacteria. Teixobactin's inhibition of peptidoglycan synthesis is further explained by Ling's finding of a buildup of undecaprenyl-N-acetylmuramic acid-pentapeptide, a crucial step in the biosynthesis of peptidoglycan. According to Ling's tests, teixobactin is capable of inhibiting peptidoglycan synthesis by binding to either lipid I, lipid II, and undecaprenyl pyrophosphate. Teixobactin also seemed to be specifically involved with peptidoglycan precursors rather than blocking enzyme activity.",
            "score": 73.4163818359375
        },
        {
            "docid": "501183_8",
            "document": "FtsZ . Much is known about the dynamic polymerization activities of tubulin and microtubules, but little is known about these activities in FtsZ. While it is known that single-stranded tubulin protofilaments form into 13 stranded microtubules, the multistranded structure of the FtsZ-containing Z-ring is not known. It is only speculated that the structure consists of overlapping protofilaments. Nevertheless, recent work with purified FtsZ on supported lipid bilayers as well as imaging FtsZ in living bacterial cells revealed that FtsZ protofilaments have polarity and move in one direction by treadmilling (see also below).",
            "score": 72.99079132080078
        },
        {
            "docid": "23890524_15",
            "document": "Eukaryotic ribosome (80S) . The ribosome is a prominent drug target and many antibacterials interfere with translation at different stages of the elongation cycle Most clinically relevant translation compounds are inhibitors of bacterial translation, but inhibitors of eukaryotic translation may also hold therapeutic potential for application in cancer or antifungal chemotherapy. Elongation inhibitors show antitumor activity 'in vivo' and 'in vitro'. One inhibitor of eukaryotic translation elongation is the glutarimide antibiotic cycloheximide (CHX), which was co-crystallized with the eukaryotic 60S subunit and binds in the ribosomal E-site. The structural characterization of the eukaryotic ribosome enables the use of structure-based methods for the design of novel therapeutics, and allows the structural differences to the bacterial ribosome to be exploited, improving the selectivity and drug and therefore reducing adverse effects.",
            "score": 72.4259262084961
        },
        {
            "docid": "106256_31",
            "document": "Allosteric regulation . Allostery is a direct and efficient means for regulation of biological macromolecule function, produced by the binding of a ligand at an allosteric site topographically distinct from the orthosteric site. Due to the often high receptor selectivity and lower target-based toxicity, allosteric regulation is also expected to play an increasing role in drug discovery and bioengineering. The AlloSteric Database (ASD, http://mdl.shsmu.edu.cn/ASD) provides a central resource for the display, search and analysis of the structure, function and related annotation for allosteric molecules. Currently, ASD contains allosteric proteins from more than 100 species and modulators in three categories (activators, inhibitors, and regulators). Each protein is annotated with detailed description of allostery, biological process and related diseases, and each modulator with binding affinity, physicochemical properties and therapeutic area. Integrating the information of allosteric proteins in ASD should allow the prediction of allostery for unknown proteins, to be followed with experimental validation. In addition, modulators curated in ASD can be used to investigate potential allosteric targets for a query compound, and can help chemists to implement structure modifications for novel allosteric drug design.",
            "score": 72.18289947509766
        },
        {
            "docid": "722565_2",
            "document": "Ketolide . Ketolides are antibiotics belonging to the macrolide group. Ketolides are derived from erythromycin by substituting the cladinose sugar with a keto-group and attaching a cyclic carbamate group in the lactone ring. These modifications give ketolides much broader spectrum than other macrolides. Moreover, ketolides are effective against macrolide-resistant bacteria, due to their ability to bind at two sites at the bacterial ribosome as well as having a structural modification that makes them poor substrates for efflux-pump mediated resistance. Ketolides block protein synthesis by binding to ribosomal subunits and may also inhibit the formation of newly forming ribosomes. According to a recent study comparing the action of the classic macrolides erythromycin and azithromycin with ketolides, which are used to treat serious infections, the more powerful drugs (ketolides) were the more \"leaky\" in blocking the production of proteins. The researchers were surprised to discover that ketolides, which are known to be better antibiotics, allow for many more proteins to be made compared to the older, less efficient macrolides. As a result, it is now believed that allowing cells to make some proteins could be much more damaging for a microbe than not letting it make any proteins at all. The findings may point the way to better and more potent antibiotics.",
            "score": 72.16057586669922
        },
        {
            "docid": "48232306_17",
            "document": "Halictus sexcinctus . With the rise of antibiotic resistant bacteria, the need to find antimicrobial substances that function differently than current antibiotics is incredibly important. Antimicrobial peptides (AMPs) are commonly found in the venom of arthropods, and these proteins function by breaking up bacterial cell membranes. However, these AMPs will often also damage eukaryotic cells, typically red blood cells. A substance that damages human red blood cells will be less valuable as an antibiotic for obvious reasons. AMPs that damaged red blood cells at low rates were found in the venom of several species of bees, leading to a study of the venom of \"H. sexcinctus. \"Two newly isolated peptides from the venom were found to be significantly different in structure to any other AMPs in the antimicrobial peptide database. These new proteins showed effective antimicrobial activity against four strains of bacteria (\"B. subtilis\", \"S. aureus\", \"E. coli\", and \"P. aeruginosa\") and a yeast pathogen (\"C. albicans\"). While these proteins isolated from \"H. sexcinctus\" venom show good antimicrobial properties, they also show found to damage red blood cells (hemolysis), reducing their therapeutic potential. However, when their structures were modified a few analogs with slightly lower hemolytic activity were discovered, meriting further study.\"",
            "score": 71.92745208740234
        },
        {
            "docid": "1914_3",
            "document": "Antimicrobial resistance . Resistance arises through one of three mechanisms: natural resistance in certain types of bacteria, genetic mutation, or by one species acquiring resistance from another. All classes of microbes can develop resistance. Fungi develop antifungal resistance. Viruses develop antiviral resistance. Protozoa develop antiprotozoal resistance, and bacteria develop antibiotic resistance. Resistance can appear spontaneously because of random mutations. However, extended use of antimicrobials appears to encourage mutations which can render antimicrobials ineffective. Preventive measures include only using antibiotics when needed, thereby stopping misuse of antibiotics or antimicrobials. Narrow-spectrum antibiotics are preferred over broad-spectrum antibiotics when possible, as effectively and accurately targeting specific organisms is less likely to cause resistance. For people who take these medications at home, education about proper use is essential. Health care providers can minimize spread of resistant infections by use of proper sanitation and hygiene, including handwashing and disinfecting between patients, and should encourage the same of the patient, visitors, and family members. Rising drug resistance is caused mainly by use of antimicrobials in humans and other animals, and spread of resistant strains between the two. Growing resistance has also been linked to dumping of inadequately treated effluents from the pharmaceutical industry, especially in countries where bulk drugs are manufactured. Antibiotics increase selective pressure in bacterial populations, causing vulnerable bacteria to die; this increases the percentage of resistant bacteria which continue growing. Even at very low levels of antibiotic, resistant bacteria can have a growth advantage and grow faster than vulnerable bacteria. With resistance to antibiotics becoming more common there is greater need for alternative treatments. Calls for new antibiotic therapies have been issued, but new drug development is becoming rarer.",
            "score": 71.56130981445312
        },
        {
            "docid": "19178965_69",
            "document": "Fungus . Many species produce metabolites that are major sources of pharmacologically active drugs. Particularly important are the antibiotics, including the penicillins, a structurally related group of \u03b2-lactam antibiotics that are synthesized from small peptides. Although naturally occurring penicillins such as penicillin G (produced by \"Penicillium chrysogenum\") have a relatively narrow spectrum of biological activity, a wide range of other penicillins can be produced by chemical modification of the natural penicillins. Modern penicillins are semisynthetic compounds, obtained initially from fermentation cultures, but then structurally altered for specific desirable properties. Other antibiotics produced by fungi include: ciclosporin, commonly used as an immunosuppressant during transplant surgery; and fusidic acid, used to help control infection from methicillin-resistant \"Staphylococcus aureus\" bacteria. Widespread use of antibiotics for the treatment of bacterial diseases, such as tuberculosis, syphilis, leprosy, and others began in the early 20th century and continues to date. In nature, antibiotics of fungal or bacterial origin appear to play a dual role: at high concentrations they act as chemical defense against competition with other microorganisms in species-rich environments, such as the rhizosphere, and at low concentrations as quorum-sensing molecules for intra- or interspecies signaling. Other drugs produced by fungi include griseofulvin isolated from \"Penicillium griseofulvum\", used to treat fungal infections, and statins (HMG-CoA reductase inhibitors), used to inhibit cholesterol synthesis. Examples of statins found in fungi include mevastatin from \"Penicillium citrinum\" and lovastatin from \"Aspergillus terreus\" and the oyster mushroom. Fungi produce compounds that inhibit viruses and cancer cells. Specific metabolites, such as polysaccharide-K, ergotamine, and \u03b2-lactam antibiotics, are routinely used in clinical medicine. The shiitake mushroom is a source of lentinan, a clinical drug approved for use in cancer treatments in several countries, including Japan. In Europe and Japan, polysaccharide-K (brand name Krestin), a chemical derived from \"Trametes versicolor\", is an approved adjuvant for cancer therapy.",
            "score": 71.337158203125
        },
        {
            "docid": "46489321_5",
            "document": "Antibiotic synergy . Current research on antibiotic synergy and potential therapies is moving in three primary directions. Some research is devoted to finding combinations of extant antibiotics which when combined exhibit synergy. A classic example of this effect is the interaction between \u03b2-lactams, which damage the bacteria cell membrane, and aminoglycosides, which inhibit protein synthesis. The damage dealt to the cell wall by \u03b2-lactams allows more aminoglycoside molecules to be taken up into the cell than would otherwise be possible, enhancing cell damage. In some cases, antibacterial combinations restore potency to ineffective drugs. Other research has been devoted to finding antibiotic resistance breakers (ARB\u2019s) which enhance an antibiotic\u2019s potency. This effect is mediated through direct antibacterial activity of the ARB, targeting and destroying mechanisms of bacterial resistance thereby allowing the antibiotic to function properly, interacting with the host to trigger defensive mechanisms, or some combination thereof. The third direction of research involves combining traditional antibiotics with unconventional bactericides such as silver nano particles. Silver nano particles have strong non-specific interactions with bacterial cells that result in cell wall deformation and the generation of damaging reactive oxygen species (ROS) in the presence of cellular components. These effects are thought to weaken bacterial cells, making them more susceptible to assault from conventional antibiotics.",
            "score": 71.3325424194336
        },
        {
            "docid": "53960307_4",
            "document": "Andreas Peschel . Peschel's research focuses on the biology and pathogenicity of the bacterium \"Staphylococcus aureus\", a major cause of severe human infections. Multidrug-resistant \"S. aureus\" such as methicillin-resistant \"S. aureus\" (MRSA) represent a major cause of morbidity and mortality worldwide demanding new strategies for prevention and therapy of staphylococcal infections. The symptomless colonization of the human nose by \"S. aureus\" represents a major risk factor for invasive \"S. aureus\" infections. Peschel's laboratory pioneered research on the strategies used by \"S aureus\" to colonize the human nose and elude the immune system to cause infections. In 2016 his team demonstrated that many nasal bacteria produce antimicrobial compounds such as the novel antibiotic \"lugdunin\" that may become novel drugs against bacterial infections and may be used to prevent pathogen colonization. Peschel is a principal investigator of the German Center for Infection Research (DZIF), which connects basic and translational research on major infectious diseases.",
            "score": 71.30255126953125
        },
        {
            "docid": "1551873_30",
            "document": "ATP-binding cassette transporter . Bacterial drug resistance has become an increasingly major health problem. One of the mechanisms for drug resistance is associated with an increase in antibiotic efflux from the bacterial cell. Drug resistance associated with drug efflux, mediated by P-glycoprotein, was originally reported in mammalian cells. In bacteria, Levy and colleagues presented the first evidence that antibiotic resistance was caused by active efflux of a drug. P-glycoprotein is the best-studied efflux pump and as such has offered important insights into the mechanism of bacterial pumps. Although some exporters transport a specific type of substrate, most transporters extrude a diverse class of drugs with varying structure. These transporters are commonly called multi-drug resistant (MDR) ABC transporters and sometimes referred to as \"hydrophobic vacuum cleaners\".",
            "score": 71.27124786376953
        },
        {
            "docid": "42057374_3",
            "document": "Chem-seq . A substantial number of small-molecule ligands, including therapeutic drugs, elicit their effects by binding specific proteins associated with the genome. Mapping the global interactions of these chemical entities with chromatin in a genome-wide manner could provide insights into the mechanisms by which a small molecule influences cellular functions. When combined with other chromatin analysis techniques such as ChIP-seq, Chem-seq can be utilized to investigate the genome-wide effects of therapeutic modalities and to understand the effects of drugs on nuclear architecture in various biological contexts. In a broader sense, these methods will be useful to enhance our understanding of the therapeutic mechanisms through which small molecules modulate the function and activity of genome-associated proteins. Through the identification of the cellular targets of a drug, it becomes possible to gain an increased understanding of the causes of side effects and toxicity in the early stages of drug development, which should help to reduce the attrition rate in development.",
            "score": 71.21327209472656
        }
    ]
}